Adjuvant hormonal therapy use among insured, low-income women with breast cancer. - Wikidata - wikimedia - TriplyDB

Adjuvant hormonal therapy use among insured, low-income women with breast cancer.

Adjuvant hormonal therapy use among insured, low-income women with breast cancer.

http://www.wikidata.org/entity/Q37280714

about

Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer Factors Associated with Adherence to Adjuvant Endocrine Therapy Among Privately Insured and Newly Diagnosed Breast Cancer Patients: A Quantile Regression Analysis Factors influencing adherence to cancer treatment in older adults with cancer: a systematic review Racial/Ethnic and socioeconomic disparities in endocrine therapy adherence in breast cancer: a systematic review Endocrine therapy use among elderly hormone receptor-positive breast cancer patients enrolled in Medicare Part D Predicting Late-stage Breast Cancer Diagnosis and Receipt of Adjuvant Therapy: Applying Current Spatial Access to Care Methods in Appalachia Adjuvant therapy use among Appalachian breast cancer survivors CYP2D6 genotyping and tamoxifen: an unfinished story in the quest for personalized medicine.Cancer outcomes in low-income elders: is there an advantage to being on Medicaid?Predicting Adherence to Aromatase Inhibitor Therapy among Breast Cancer Survivors: An Application of the Protection Motivation Theory.Treatment adherence in chronic myeloid leukaemia patients receiving tyrosine kinase inhibitors American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.Adherence to hormone therapy among women with breast cancer Early discontinuation of endocrine therapy for breast cancer: who is at risk in clinical practice?A prospective cohort study of early discontinuation of adjuvant chemotherapy in women with breast cancer: the breast cancer quality of care study (BQUAL).Racial disparities in initiation of adjuvant endocrine therapy of early breast cancer.A nation-wide multicenter 10-year (1999-2008) retrospective clinical study of endocrine therapy for Chinese females with breast cancer.Frailty and adherence to adjuvant hormonal therapy in older women with breast cancer: CALGB protocol 369901.Risk of a second breast cancer associated with hormone-receptor and HER2/neu status of the first breast cancer.Early discontinuation of adjuvant hormone therapy is associated with a poor prognosis in Japanese breast cancer patients.Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients Factors associated to persistence with hormonal therapy in women with breast cancer.The change from brand-name to generic aromatase inhibitors and hormone therapy adherence for early-stage breast cancer.Women with breast cancer taking chemotherapy: depression symptoms and treatment adherence Joint pain severity predicts premature discontinuation of aromatase inhibitors in breast cancer survivors.Household net worth, racial disparities, and hormonal therapy adherence among women with early-stage breast cancer.Adjuvant hormonal therapy use among women with ductal carcinoma in situ.Adherence to adjuvant hormonal therapy and its relationship to breast cancer recurrence and survival among low-income women Adjuvant chemotherapy for breast cancer in patients with schizophrenia Racial/ethnic differences in initiation of adjuvant hormonal therapy among women with hormone receptor-positive breast cancer.The introduction of generic aromatase inhibitors and treatment adherence among Medicare D enrollees.Nomogram to predict the benefit of radiation for older patients with breast cancer treated with conservative surgery.Use of a urine anastrozole assay to determine treatment discontinuation among women with hormone-sensitive breast cancer: a pilot study Endocrine therapy initiation from 2001 to 2008 varies by age at breast cancer diagnosis and tumor size.Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer.Prescription drug coverage: implications for hormonal therapy adherence in women diagnosed with breast cancer Noninitiation of adjuvant chemotherapy in women with localized breast cancer: the breast cancer quality of care study Patient-reported discontinuation of endocrine therapy and related adverse effects among women with early-stage breast cancer The Breast Cancer Quality of Care Study (BQUAL): a multi-center study to determine causes for noncompliance with breast cancer adjuvant therapy.Adherence to adjuvant hormone therapy in low-income women with breast cancer: the role of provider-patient communication

P2860

Q24632347-7BC87672-4940-4C57-8E9C-4C5D248FA9F2 Q26779595-0BD39615-8EF8-42E4-9D23-2745E82A99E6 Q26850736-A2D3053C-D383-4B2D-9DAC-C4B73ED0F756 Q28082674-657A8540-4BBE-422B-B495-1A3FE5029F8C Q28657951-A5B181FB-D720-4E71-9461-80ACE1A3B281 Q30278530-C5AC8679-7F6F-4934-B885-E6E7527C4EA7 Q30279083-04584EDF-1493-4F76-B982-C78369B98BE7 Q30400967-C10CC1C5-A05C-45DE-8DA0-66571CD79E6F Q33551498-9EBA640D-B2C3-44BF-9935-90A9CF2ABCE9 Q33562869-6A53D520-1BF4-4332-91F3-778DA701F34E Q33603379-8D7C8782-45FB-4D0A-8649-763AF72E32DA Q33631047-A50EE218-C971-4A17-9B24-338BDB1F6057 Q33755452-908179EC-024E-459C-979E-3C2F04F8D7BA Q33756969-41BF875F-EB35-4FAD-B763-B852DD842D2B Q33857602-A4A3A529-48EA-4ACD-B1EF-9D5C3870B719 Q33877830-942A7BD3-38C8-420E-968B-B4264FF32B13 Q33921197-85D3B157-46A4-4AD8-9D4C-1810B10F7391 Q33927985-E1BE1AD0-291B-4A99-99FD-83C2311C017A Q33946233-EF4C77C2-19B1-4DF5-8C8E-11C5585EDB2B Q34174599-4FA70524-C34E-4F5B-8D5C-2890949C1B5F Q34193946-71C9A4EB-AFDB-492C-B73A-E72EF3501BFA Q34386558-79D2BE4D-8BDC-4EF9-9893-EB6CDDDC0D76 Q34736154-032BED53-E02F-410C-A829-17E8B7C65F98 Q34935814-3CDE5CF1-11AC-436A-9F34-10F4BFFEB7DC Q34978227-C3629DB2-A475-4707-90B3-87B30208DFD6 Q35168777-DE768F7C-AD32-4A17-BF68-A8C069F10B42 Q35667931-E862A64F-A8CB-4C83-8D08-065204E975D6 Q35968741-0B226C78-C199-4DA6-B6B6-D7DE4E68EBD7 Q35995272-99EE71B9-62E1-4978-A82E-3081AEA70FAE Q36033062-A6B28C37-F876-4F19-B577-B263A215A9DB Q36087210-248824E8-35B9-4616-B3DD-2B335023781A Q36135193-1C3AB72F-FEB7-4D4E-BAF0-485E0AB0CDAE Q36226324-4EF21950-4D0B-4757-A07B-2359C48E322F Q36278395-2783EB29-D3C3-4BEA-AD1A-48330CEC23F5 Q36292773-3E20B095-16A1-48C1-B054-66F3D13FF17B Q36300005-8257D6F0-C69F-4289-A37A-516903A3E14D Q36339703-15F52D2B-B2A7-4E59-B048-8C1C13DE9992 Q36406107-B72A61BD-41EA-499B-B448-045B813F4E12 Q36459112-FAF8F171-9E55-47C8-B9D9-99DE9F0D2E79 Q36556940-09431534-7BAD-438F-9D60-FF717326BB05

P2860

Adjuvant hormonal therapy use among insured, low-income women with breast cancer.

http://www.wikidata.org/entity/Q37280714

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 18 May 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Adjuvant hormonal therapy use among insured, low-income women with breast cancer.

@en

Adjuvant hormonal therapy use among insured, low-income women with breast cancer.

@nl

type

label

Adjuvant hormonal therapy use among insured, low-income women with breast cancer.

@en

Adjuvant hormonal therapy use among insured, low-income women with breast cancer.

@nl

prefLabel

Adjuvant hormonal therapy use among insured, low-income women with breast cancer.

@en

Adjuvant hormonal therapy use among insured, low-income women with breast cancer.

@nl

P1433

Q37280714-8ACD12E4-20C8-4A3B-9A59-CFF4960C6A31

P1476

Q37280714-A6FCE8C1-0B2B-4649-9490-FDB446F73698

P2093

Q37280714-0B978AAC-48D1-42FF-B3DC-A3A9A1E2B1BA

Q37280714-0DBD563A-E2A8-4E90-83F4-5FD6B2277905

Q37280714-4E7B81E7-2006-47AD-8630-1AF38D1FE4FD

Q37280714-992EDC49-17A5-4C5E-9B05-851AC6BDC959

Q37280714-BA8D9646-52DA-41D8-92BA-FB9536C36ECD

Q37280714-E14C35E9-1BC6-4F9F-94F9-66C4FA6F58A7

P2860

Q37280714-0E3229C2-C732-4821-8398-22531FFC0A0F

Q37280714-0FA8F04D-7DD0-493C-B392-C200C5686E1E

Q37280714-1B59CE0F-D9A0-43D6-947B-DBDC60CE7D7D

Q37280714-1FD2914A-469C-464C-A8F4-4D0F5532A876

Q37280714-261057D9-F5BF-4736-9AEF-90E8FFD08AB7

Q37280714-2898DB25-8844-4530-A8A0-0F187278791E

Q37280714-29BAA287-7521-4D36-AFAD-BA4CF5A8BFA5

Q37280714-2D85C9E9-096F-47B5-9909-52A741737D70

Q37280714-2DAE9BD5-AD91-4F21-81BA-60D1EA3F7449

Q37280714-348FAB65-58D7-4562-A08E-C67ACD8F2F54

P304

Q37280714-297DFCDE-0363-4F1A-9406-FD4AB65F8C2A

P31

Q37280714-514B1D23-FDD8-4BF1-B278-5C9BC0A844C8

P356

Q37280714-F1D49145-8B46-4E55-8DDD-AD30142BD91F

P407

Q37280714-0F742420-1DFF-4815-9A35-E1FC0E5FDA12

P433

Q37280714-9806D991-621F-46E1-A47E-E4A2FC0AEDD9

P478

Q37280714-56C64854-1A14-4DE4-801D-4E26F7A79B14

P577

Q37280714-A14056A9-F93E-4DAC-9B1F-F35727AF00B7

P698

Q37280714-581FD67A-6DF3-4BBB-ADC2-56C9AB58A15A

P932

Q37280714-826189DE-7F16-40A3-9476-F0F009FB0D11

P356

JCO.2008.19.2419

P1433

Journal of Clinical Oncology

P1476

Adjuvant hormonal therapy use among insured, low-income women with breast cancer.

@en

P2093

Fabian Camacho

http://www.w3.org/2001/XMLSchema#string

Gretchen Kimmick

http://www.w3.org/2001/XMLSchema#string

Monali Bhosle

http://www.w3.org/2001/XMLSchema#string

Rajesh Balkrishnan

http://www.w3.org/2001/XMLSchema#string

Roger Anderson

http://www.w3.org/2001/XMLSchema#string

Wenke Hwang

http://www.w3.org/2001/XMLSchema#string

P2860

Adherence to Medication

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Population-based persistency rates for topical glaucoma medications measured with pharmacy claims data.

Estimating medication persistency using administrative claims data.

Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23.

Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women.

Social support and patient adherence to medical treatment: a meta-analysis.

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.

Adherence beliefs among breast cancer patients taking tamoxifen.

P304

3445-3451

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2008.19.2419

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P577

2009-05-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19451445

http://www.w3.org/2001/XMLSchema#string

P932

2717752

http://www.w3.org/2001/XMLSchema#string